✦ LIBER ✦

Characteristics of patients with chronic hepatitis B in France: Predominant frequency of HBe antigen negative cases

✍ Scribed by Jean-Pierre Zarski; Patrick Marcellin; Vincent Leroy; Christian Trepo; Didier Samuel; Nathalie Ganne-Carrie; Karl Barange; Valérie Canva; Michel Doffoel; Paul Cales

Book ID: 116651101
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 125 KB
Volume: 45
Category: Article
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2006.03.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P.009 Epidemiological characteristics of

P.009 Epidemiological characteristics of HBV inactive chronic carriers and comparison with hbe antigen negative chronic hepatitis B patients

✍ J. Zarski; P. Marcellin; V. Leroy 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 263 KB

Comparison of anti-HBe-positive and HBe-

Comparison of anti-HBe-positive and HBe-antigen-positive chronic hepatitis B in France

✍ Jean Pierre Zarski; Patrick Marcellin; Marielle Cohard; Jean Michel Lutz; Cather 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 384 KB

1171 Molecular epidemiology of hepatitis

1171 Molecular epidemiology of hepatitis B virus in patients with HBEAG-negative/anti-HBE-positive chronic hepatitis B from different geographical areas. Data from the PEGASYs® study in HBE-antigen-negative CHB

✍ BRUNETTO, M; MAINA, A; OLIVERI, F; BONINO, F; COLUCCI, G; MARCELLIN, P; LAU, G; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB

Four years of treatment with lamivudine:

Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B

✍ S. Gaia; A. Marzano; A. Smedile; V. Barbon; M. L. Abate; A. Olivero; M. Lagget; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

Efficacy of lamivudine in patients with

Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB

✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60

Long-term follow-up of patients with hep

Long-term follow-up of patients with hepatitis B e antigen negative chronic hepatitis B

✍ Dan Bekku; Makoto Arai; Fumio Imazeki; Yutaka Yonemitsu; Tatsuo Kanda; Keiichi F 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 316 KB